Use lay language. The Covid-19 pandemic hit France in March 2020 and stage 3 of the epidemic justified the introduction of national and unprecedented containment measures from March 17, 2020. The Montpellier CHU experienced peak hospitalizations of Covid-19 infections in late March. The estimate of the proportion of infected people in Occitania, South of France, for the 11th of May 2020 is 3.1% (95% CI: 1.9-5.9) for the Occitania region, to which Montpellier belongs. In the context of the Covid-19 epidemic, notably due to the absence of pharmacological or vaccine prophylaxis, barrier measures were of crucial importance, especially for exposed caregivers. These measures include an adaptation of individual behavior, the creation of a so-called "Covid" hospital, the wearing of specific equipment in all departments, the use in the rooms of Covid-19 patients of a gown, an apron, gloves, and a FFP2 type mask in the event of contact and sampling, protocolized and standardized bio-cleaning measures, a reorganization of the premises and the definition of specific circuits. In view of the second wave of the epidemic, estimating the effectiveness of the barrier measures is of major importance. The investigators therefore propose an evaluation of the effectiveness of these measures, by comparing the serological prevalence of infection among caregivers working directly in COVID units compared to caregivers working in services excluding the management of Covid-19 patients. Systematic evaluation in COVID-19 units of Sarc-Co-V2 infection will also be assessed, with naso-pharyngeal swabs.
Other: Survey
questionnaire on their symptoms and their exposures
Inclusion criteria:
- exposed group: exposed caregivers and agents who worked in COVID units (medicine,
resuscitation, screening) until their date of collection. An exposed agent or
caregiver is defined by the entrance of rooms with a COVID-19 infection during their
professional activity.
- low or unexposed group: caregivers or agents who have worked in non-COVID units in a
non-COVID hospital
Exclusion criteria:
- refusal to participate
Uh Montpellier
Montpellier, France
Investigator: Marie Bistoquet, MB
m-bistoquet@chu-montpellier.fr
Alain MAKINSON, MCU-PH
0663075260 - 33
a-makinson@chu-montpellier.fr
Marie Bistoquet, MD
m-bistoquet@chu-montpellier.fr
Marie Bistoquet, MD, Principal Investigator
University Hospital, Montpellier